Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Finger stick blood test to assess postvaccination SARS-CoV-2 neutralizing antibody response against variants

Finger stick blood test to assess postvaccination SARS-CoV-2 neutralizing antibody response against variants

Thumbnail Image
Download
Name

Bioengineering Transla Med - 2022 - Lim - Finger stick blood test to assess postvaccination SARS‐CoV‐2 neutralizing.pdf

Description
Published version
Size

7.65 MB

Format

Adobe PDF

Checksum (MD5)

aa8acc7b45381274e9af15e182f114b4

sword-2025-12-12T22:52:02.original.xml (130 B)
Original SWORD entry document
Author(s)
Lim, Sing Mei
•
Cheng, Hoi Lok
•
Jia, Huan
•
Kongsuphol, Patthara
•
D/O Shunmuganathan, Bhuvaneshwari
•
Chen, Ming Wei
•
Ng, Say Yong
•
Gao, Xiaohong
•
Turaga, Shuvan Prashant
•
Heussler, Sascha P
more
Date Issued
January 22, 2022
Journal
Bioengineering & Translational Medicine
Publisher
Wiley
Citation
Lim, Sing Mei, Cheng, Hoi Lok, Jia, Huan, Kongsuphol, Patthara, D/O Shunmuganathan, Bhuvaneshwari et al. 2022. "Finger stick blood test to assess postvaccination SARS-CoV-2 neutralizing antibody response against variants." Bioengineering & Translational Medicine, 7 (2).
Version
Final published version
Abstract
There is clinical need for a quantifiable point-of-care (PoC) SARS-CoV-2 neutralizing antibody (nAb) test that is adaptable with the pandemic's changing landscape. Here, we present a rapid and semi-quantitative nAb test that uses finger stick or venous blood to assess the nAb response of vaccinated population against wild-type (WT), alpha, beta, gamma, and delta variant RBDs. It captures a clinically relevant range of nAb levels, and effectively differentiates prevaccination, post first dose, and post second dose vaccination samples within 10 min. The data observed against alpha, beta, gamma, and delta variants agrees with published results evaluated in established serology tests. Finally, our test revealed a substantial reduction in nAb level for beta, gamma, and delta variants between early BNT162b2 vaccination group (within 3 months) and later vaccination group (post 3 months). This test is highly suited for PoC settings and provides an insightful nAb response in a postvaccinated population.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Terms of Use
Creative Commons Attribution
https://creativecommons.org/licenses/by/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/164320
DOI of Published Version
https://doi.org/10.1002/btm2.10293
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.